Scarica l'app Stockscreener
56.99
16.71%
8.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$48.54
Aprire:
$49
Volume 24 ore:
10.99M
Relative Volume:
1.40
Capitalizzazione di mercato:
$22.59B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-6.9959
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+24.86%
1M Prestazione:
+8.73%
6M Prestazione:
+130.85%
1 anno Prestazione:
+132.36%
Intervallo 1D:
$48.98
$56.99
Intervallo di 1 settimana:
$45.29
$56.80
Portata 52W:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
56.93 | 19.26B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
428.31 | 107.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.04 | 74.34B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
784.58 | 48.96B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.35 | 39.51B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
315.08 | 32.89B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Why is Moderna stock surging today? By Investing.com - Investing.com Canada
Moderna Stock Rises On Positive Phase 3 Flu Data: What Investors Need To Know - Benzinga
Moderna Stock Climbs After Hantavirus Vaccine: Data Triggers Analyst Price Target - Investing.com
Moderna Inc. stock (US60770K1034): Shares rebound after earnings and strong 2026 run-up - AD HOC NEWS
CHINA SHOTO : 9000 Leverage Shares 3x Long Moderna (MRNA) ETP Securities - marketscreener.com
Moderna Stock Climbs After Hantavirus Vaccine Data Release - Tokenist
Gateway Investment Advisers LLC Acquires 131,364 Shares of Moderna, Inc. $MRNA - MarketBeat
5 Insightful Analyst Questions From Moderna’s Q1 Earnings Call - The Globe and Mail
Hantavirus: What to Know About the Virus—and Why Moderna Stock Rallied - Barron's
Investors Buy Large Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Moderna Stock Rallied on Hantavirus Fears. What to Know. - Barron's
Moderna stock holds steady amid regulatory review of mRNA-1010 in US, EU, Canada, Australia - Traders Union
Moderna stock jumps 10% amid hantavirus outbreak concerns By Investing.com - Investing.com Canada
Brookline Capital Markets Forecasts Moderna FY2026 Earnings - MarketBeat
NVAX Stock Eyes Breakout Week: Novavax Claims Patients Were ‘Twice As Likely’ To Pick Its COVID Shot Over Moderna Again - Stocktwits
MRNA Stock Quote Price and Forecast - CNN
MRNA SEC FilingsModerna 10-K, 10-Q, 8-K Forms - Stock Titan
Moderna Shareholders OK Directors, Executive Pay Votes and Ernst & Young as 2026 Auditor at AGM - Yahoo Finance
Is Wall Street Bullish or Bearish on Moderna Stock? - Yahoo Finance
Moderna flu vaccine shows superior efficacy in phase 3 study By Investing.com - Investing.com Australia
Moderna flu vaccine shows superior efficacy in phase 3 study - Investing.com
Moderna's flu shot heads to FDA decision after NEJM Phase 3 data - Stock Titan
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 - Weatherford Democrat
Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial - Reuters
Moderna's mRNA flu vaccine is more effective than the standard shot in a late-stage trial - AOL.com
Moderna stands as the best performing large-cap healthcare stock YTD - MSN
FDA halts publication of studies on COVID, shingles vaccines - Seeking Alpha
Brookline Capital Markets Weighs in on Moderna Q2 Earnings - MarketBeat
Non-covid mRNA Vaccine and Therapeutics Market Supply Chain Analysis and Revenue Forecast 2026 to 2035 - openPR.com
Moderna (MRNA) Receives a Buy from Piper Sandler - The Globe and Mail
Sigma Planning Corp Makes New $907,000 Investment in Moderna, Inc. $MRNA - MarketBeat
Abbas Hussain Sells 5,682 Shares of Moderna (NASDAQ:MRNA) Stock - MarketBeat
Moderna director Abbas sells $264,951 in shares - Investing.com
Sandra Horning at Moderna (NASDAQ: MRNA) gains 16,233 shares via RSU vesting - Stock Titan
Director Rubenstein acquires 8,116 Moderna (NASDAQ: MRNA) shares - Stock Titan
Tax-driven stock sale by Moderna (MRNA) director after RSU vesting - Stock Titan
Director at Moderna (MRNA) receives 16,233 shares as RSUs vest - Stock Titan
Director at Moderna (NASDAQ: MRNA) receives 12,174 vested shares - Stock Titan
MRNA Maintained by RBC Capital -- Price Target Raised to $38.00 - GuruFocus
Moderna (MRNA) director converts 4,058 RSUs into common stock - Stock Titan
Moderna shares rise as investors revisit Q1 results, pipeline milestones, and fresh price-target bumps - Quiver Quantitative
Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era - 24/7 Wall St.
UBS Adjusts Price Target on Moderna to $45 From $36, Maintains Neutral Rating - marketscreener.com
Mitsubishi UFJ Trust & Banking Corp Boosts Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (MRNA) Stock Analysis: Navigating Biotech’s Challenges with 260% Revenue Growth - DirectorsTalk Interviews
The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals - The Globe and Mail
Brokers Issue Forecasts for Moderna FY2029 Earnings - MarketBeat
MRNA Q1 Deep Dive: International Partnerships and Pipeline Progress Offset Litigation Headwinds - Yahoo Finance
Moderna’s Stock Rises in 2026 as International COVID-19 Vaccine Sales Offset U.S. Decline - geneonline.com
Moderna’s strong vaccine sales outside US far surpass estimates - The Boston Globe
Moderna (MRNA) Is Down 10.6% After Q1 Loss Widened On Settlement And EU Vaccine Wins – Has The Bull Case Changed? - Yahoo Finance
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):